Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$21.33
+3.0%
$17.96
$12.21
$41.31
$654.13M-0.09596,492 shs319,755 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.67
+2.4%
$4.49
$2.21
$6.71
$592.29M1.791.13 million shs954,021 shs
Pharming Group stock logo
PHAR
Pharming Group
$8.75
+2.8%
$8.45
$6.65
$11.07
$595.27M-0.086,368 shs150 shs
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
$3.48
-4.5%
$2.99
$0.15
$1.27
$160.38M-0.4314.23 million shs29,326 shs

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%+0.73%+9.23%+18.56%-1.43%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.00%+8.06%+1.33%+21.93%+94.04%
Pharming Group stock logo
PHAR
Pharming Group
0.00%+5.99%+1.48%-5.56%-13.27%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00%+7.25%-8.07%-18.24%+1,096.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.3957 of 5 stars
4.40.00.00.02.41.70.6
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
3.3444 of 5 stars
2.31.00.04.32.73.30.6
Pharming Group stock logo
PHAR
Pharming Group
2.7075 of 5 stars
3.55.00.00.02.80.00.6
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.70
Moderate Buy$33.6357.64% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5017.77% Upside
Pharming Group stock logo
PHAR
Pharming Group
3.00
Buy$30.00242.86% Upside
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RTTR, ORGO, ANAB, and PHAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/20/2025
Pharming Group stock logo
PHAR
Pharming Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00 ➝ $37.00
3/14/2025
Pharming Group stock logo
PHAR
Pharming Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.00
3/14/2025
Pharming Group stock logo
PHAR
Pharming Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00 ➝ $37.00
3/5/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$36.00 ➝ $42.00
3/5/2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $6.00
3/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.00
3/3/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
2/13/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$40.00 ➝ $51.00
2/12/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
2/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M7.17N/AN/A$3.32 per share6.42
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$482.04M1.23$0.30 per share15.72$2.11 per share2.21
Pharming Group stock logo
PHAR
Pharming Group
$297.20M2.00$0.10 per share91.82$3.26 per share2.68
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/A$0.10 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$163.62M-$5.21N/AN/AN/A-289.75%-287.94%-37.25%5/8/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.02N/AN/AN/A-1.62%-2.69%-1.63%5/8/2025 (Estimated)
Pharming Group stock logo
PHAR
Pharming Group
-$10.55M-$0.17N/A291.67N/A-6.09%-7.65%-3.82%5/6/2025 (Estimated)
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
-$10.13MN/AN/AN/AN/AN/A-162.05%N/A

Latest RTTR, ORGO, ANAB, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30N/AN/AN/A$15.27 millionN/A
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-$0.03N/AN/AN/A$90.77 millionN/A
3/13/2025Q4 2024
Pharming Group stock logo
PHAR
Pharming Group
$0.07$0.05-$0.02$0.05$76.67 million$92.70 million
2/27/2025Q4 2024
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Pharming Group stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
10.23
10.23
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74
Pharming Group stock logo
PHAR
Pharming Group
0.41
3.53
2.76
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/A
3.67
3.67

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Pharming Group stock logo
PHAR
Pharming Group
0.03%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.84%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.70%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
36.90%
Pharming Group stock logo
PHAR
Pharming Group
2.07%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
15.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10030.67 million20.17 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.83 million79.33 millionOptionable
Pharming Group stock logo
PHAR
Pharming Group
28068.03 million66.62 millionNot Optionable
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
746.15 millionN/ANot Optionable

Recent News About These Companies

John Ritter Biography & Movies
Jeff Ritter
Dr. John D. Ritter
Kristen Ritter
Dr. Harold K. Ritter
Gary W. Ritter, Ph.D.
Ritter Public Library in Vermilion adds book club

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$21.33 +0.63 (+3.04%)
Closing price 04:00 PM Eastern
Extended Trading
$21.32 0.00 (-0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.67 +0.11 (+2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$4.68 +0.00 (+0.11%)
As of 05:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$8.75 +0.24 (+2.82%)
Closing price 04/28/2025
Extended Trading
$8.76 +0.01 (+0.06%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Ritter Pharmaceuticals stock logo

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.